Rewritten: The type of assay used is PubChem BioAssay, which serves as a counterscreen for activators of kallikrein-7 (K7) zymogen. It is a biochemical high throughput dose response assay based on fluorescence intensity, which detects optically interfering activators that hinder the measurement of EDANS-DABCYL fluorescence. This is a confirmatory assay classified as binding. Does the molecule exhibit efficacy in this assay?